RASGEF1C

Across TCGA pan-cancer cohorts, RASGEF1C RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of RASGEF1C’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where RASGEF1C RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RASGEF1C is over-expressed in tumor, although a few such as BLCA and COAD show the opposite, repressed pattern.

KIRP, BLCA, and COAD are the cancer types where RASGEF1C tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RASGEF1C RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	Male	II,III,IV	+1.539	<.001	11	view →
BLCA	Male	IV	−0.950	<.001	11	view →
COAD	Male	II,III,IV	−0.837	<.001	11	view →
KICH	All	All	−0.275	<.001	8	view →
BRCA	All	III,IV	−0.972	<.001	6	view →
KIRC	Male	All	+0.449	<.001	6	view →
LUAD	All	All	+0.341	<.001	6	view →
READ	All	All	−1.026	.001	4	view →
STAD	All	All	−0.572	.008	4	view →
LUSC	All	All	+0.195	.001	4	view →
PRAD	All	All	−0.235	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

RASGEF1C–KIRP

Open the KIRP breakdown →